Abstract 547P
Background
Immunotherapy is now standard of care in advanced/metastatic lung cancer patients either in first line alone or in combination with chemotherapy, also in subsequent lines. Here, we presenting real world outcome with immunotherapy in lung cancer patients from India.
Methods
We performed an analysis of prospectively collected data of patients with advanced/metastatic lung cancer treated at a single academic cancer centre in India. The patient’s demographic data, treatment details, toxicity and response to treatment captured from electronic medical record of each patient. Data was analysed for safety and survival outcome.
Results
From August 2015 to September 2021, 164 eligible patients were included in this study. Median age at presentation was 59 year (range 21 year to 86 year). 82% (n=134) were male and 18% (n=34) were female (M: F 4.5:1). At presentation, 73% (n=118) were ECOG PS 0 or 1, 14.5% (n=24) were ECOG PS 2, and 12.5% (n=22) were ECOG PS 3 or 4. Out of 164, 33% (n = 54), received immunotherapy drug in first line, 46% (n = 76) in second line, 21% (n = 34) in third line and beyond. 65% (n=106) received Nivolumab, 26.5% (n=44) received Pembrolizumab, 8.5% (n=14) received Atezolizumab. Median progression free survival and median overall survival was 5 months (95% CI 3.5 to 6.5 month) and 10 months (95% CI 7.3 to 12.7 month) respectively. Overall, 3-year PFS and OS rate is 5% and 23%. Fatigue was most common seen in 15% patients, hyponatremia in 5.3%, anorexia in 2.4%. Among immune-related toxicity- pneumonitis was most common seen in 4.8%, followed by hypothyroidism in 3.8%, transaminitis and nephritis in 1.9% each, skin rash, colitis, and encephalitis in 1.4% each, adrenal insufficiency and hypophysitis in 1% each seen.
Conclusions
In real world, immunotherapy having clinically significant benefit on survival in advanced/metastatic lung cancer patients with acceptable safety profile including patients with borderline performance status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract